Free Trial

Perspective Therapeutics (CATX) Stock Forecast & Price Target

Perspective Therapeutics logo
$2.85 +0.01 (+0.35%)
(As of 12/20/2024 05:16 PM ET)

Perspective Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
8

Based on 9 Wall Street analysts who have issued ratings for Perspective Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for CATX.

Consensus Price Target

$15.14
431.33% Upside
According to the 9 analysts' twelve-month price targets for Perspective Therapeutics, the average price target is $15.14. The highest price target for CATX is $21.00, while the lowest price target for CATX is $5.00. The average price target represents a forecasted upside of 431.33% from the current price of $2.85.
Get the Latest News and Ratings for CATX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Perspective Therapeutics and its competitors.

Sign Up

CATX Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.14$19.43$19.80$14.00
Forecasted Upside431.33% Upside459.90% Upside62.03% UpsideN/A
Consensus Rating
Moderate Buy
Buy
Buy
Buy

CATX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CATX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Perspective Therapeutics Stock vs. The Competition

TypePerspective TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside431.33% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent CATX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/25/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$25.00 ➝ $16.00+300.00%
11/25/2024Bank of America
3 of 5 stars
 DowngradeBuy ➝ Neutral$24.00 ➝ $5.00+44.09%
11/22/2024Oppenheimer
3 of 5 stars
 Lower TargetOutperform ➝ Outperform$22.00 ➝ $16.00+433.33%
11/21/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00 ➝ $11.00+265.45%
10/24/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00+71.09%
9/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Germino
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00+71.01%
Rare "crisis signal" triggers for third time in U.S. market (Ad)

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

9/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
5/6/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Dhankher
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/9/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$12.00 ➝ $17.00+14.48%
11/15/2023Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$14.00+503.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:51 PM ET.


CATX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Perspective Therapeutics is $15.14, with a high forecast of $21.00 and a low forecast of $5.00.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CATX shares.

According to analysts, Perspective Therapeutics's stock has a predicted upside of 431.33% based on their 12-month stock forecasts.

Over the previous 90 days, Perspective Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.

Perspective Therapeutics has been rated by research analysts at Bank of America, Oppenheimer, Royal Bank of Canada, Truist Financial, UBS Group, and Wedbush in the past 90 days.

Analysts like Perspective Therapeutics more than other "medical" companies. The consensus rating score for Perspective Therapeutics is 2.89 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CATX compares to other companies.


This page (NYSE:CATX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners